Neuroblastoma Clinical Trials

• Age 12 months to 21 years at consent/assent.

• Histologically confirmed neuroblastoma or ganglioneuroblastoma with relapsed, refractory, progressive, or persistent high-risk disease for which no curative standard option is available.

• Measurable or evaluable disease according to revised International Neuroblastoma Response Criteria (rINRC), including MIBG-avid disease, CT/MRI-evaluable soft-tissue disease, and/or bone marrow disease.

• Tumor material available for central assessment of GD2 and B7-H3 expression; at least one target must be positive.

⁃ GD2 is treated as the core target and B7-H3 as the complementary target for correlative target-prioritization analyses.

• Prior exposure to standard neuroblastoma therapy, including anti-GD2-based therapy, unless contraindicated, unavailable, or declined for a documented medical reason.

• Lansky or Karnofsky performance score \>= 50.

• Life expectancy \>= 8 weeks.

• Recovery from clinically significant acute toxicities of prior therapy and protocol-defined washout from chemotherapy, biologics, radiation, and prior cell therapy.

• Adequate organ function: hematologic, renal, hepatic, cardiac, and pulmonary function considered sufficient by protocoldefined laboratory and clinical thresholds.

• Negative pregnancy test for patients of childbearing potential and agreement to use effective contraception during the protocol-defined period.

• Written informed consent from parent/legal guardian and assent from the participant when appropriate.